[Form 4] OnKure Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Nicholas A. Saccomano, President and CEO and a director of OnKure Therapeutics, Inc. (OKUR), reported a routine transaction on 09/22/2025 in which 88 shares of Class A Common Stock were sold to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). The sale executed in multiple trades at prices ranging from $2.60 to $2.645, producing a weighted average sale price of $2.6235. Following the transaction, the reporting person beneficially owned 3,506 shares (certain of which remain as RSUs subject to vesting conditions). The Form 4 was signed by proxy on 09/24/2025.

Insights

Corporate Governance Expert

TL;DR: Routine tax-withholding sale of vested RSUs by CEO; not indicative of company performance or strategic change.

The filing documents an automated share sale to satisfy tax-withholding obligations tied to RSU vesting, a common practice under equity compensation plans. The number of shares sold (88) is small relative to the total shares outstanding for most public companies, and the disclosure includes the weighted average sale price ($2.6235) and price range ($2.60–$2.645). This is a standard insider reporting event and does not signal a change in governance, control, or compensation policy.

Securities Analyst

TL;DR: Transaction is administrative; no material impact on share count or capital structure.

The sale was executed solely to cover tax obligations from RSU vesting under the issuer’s 2023 RSU Equity Incentive Plan. The report notes that some securities remain RSUs subject to vesting, clarifying that not all reported shares reflect immediately deliverable stock. Given the small size of the sale and its stated purpose, there is no material effect on outstanding shares or investor valuation metrics based on this filing alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Saccomano Nicholas A

(Last) (First) (Middle)

C/O ONKURE THERAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/22/2025		S(1)		88	D	$2.6235(2)	3,506(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.

2. This transaction was executed in multiple trades at prices ranging from $2.60 to $2.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

	/s/ Rogan Nunn, by power of attorney	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Nicholas A. Saccomano report on Form 4 for OKUR?

The Form 4 reports that 88 shares of Class A Common Stock were sold on 09/22/2025 to cover tax withholding from RSU vesting.

At what price were the OKUR shares sold in the reported transaction?

The sale executed in multiple trades at prices ranging from $2.60 to $2.645, with a weighted average sale price of $2.6235.

How many OKUR shares does the reporting person beneficially own after the transaction?

After the reported transaction the reporting person beneficially owned 3,506 shares, some of which are RSUs still subject to vesting conditions.

Why were the shares sold according to the Form 4?

The shares were automatically sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units under the issuer’s 2023 RSU Equity Incentive Plan.

Who signed the Form 4 filing for the reporting person?

The Form 4 was signed by /s/ Rogan Nunn, by power of attorney on 09/24/2025.